NEW YORK--(BUSINESS WIRE)--Levi & Korsinsky is investigating the Board of Directors of Cadence Pharmaceuticals Inc. (“Cadence” or “the Company”) (NasdaqGS:CADX) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Mallinckrodt plc.
Click here to learn more about the action http://zlk.9nl.com/cadence-pharmaceuticals-cadx, or call: 877-363-5972. There is no cost or obligation to you.
Under the terms of the transaction, Cadence shareholders will receive $14.00 for each share of Cadence common stock they own. The investigation concerns whether the Cadence Board breached their fiduciary duties to stockholders by failing to adequately shop the Company before agreeing to enter into this transaction, and whether Mallinckrodt plc is underpaying for Cadence shares. In particular, at least one analyst set a price target for Cadence stock at $15.00 per share.
If you own Cadence common stock and wish to obtain additional information, please contact Joseph E. Levi, Esq. either via email at firstname.lastname@example.org or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/cadence-pharmaceuticals-cadx.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut and Washington D.C. The firm’s 26 attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.